RAPP at a glance
Rapport Therapeutics, Inc. (RAPP, SEC CIK 2012593) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Rapport Therapeutics, Inc. (RAPP) shares worth $827.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Gault Cheryl on September 30, 2026 of 2,075 shares at $33.76 per share.
- In the last 90 days, RAPP insiders reported 0 open-market purchases ($0) and 21 open-market sales ($7.1M) on Form 4, a net sale of $7.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 21 sells
- Net −$7.1M
- 13F holders
- 26 funds
- $827.9M · −1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly triggered financing risk: $150.0 million ATM program established under March 2026 Form S-3ASR
- Cash runway risk: $436.1 million available, projected to fund operations into second half of 2029
- Regulatory risk: FDA clinical hold previously delayed RAP-219 DPNP development until removal in December 2025
- Development risk: RAP-219 Phase 3 program underway for drug-resistant focal onset seizures
- Licensing risk: Janssen obligations include up to $76.0 million development milestones and $40.0 million sales milestones
AI summary of the RAPP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and business highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
Item EX-99.1: Item EX-99.1
- Phase 3 FOS program initiated with FOCUS 1 and FOCUS 2 enrolling, materially advancing RAP-219 toward potential pivotal evidence
- RAP-219 China IND approved, with patient recruitment expected to begin in 4Q 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected James Healy, Robert Perez, and Raymond Sanchez as Class II directors through the 2029 annual meeting
- Director support varied, with Perez receiving 37,592,089 votes versus 41,762,713 for Healy
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results and business highlights announced for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operational details
AI summaries of RAPP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RAPP
Don't miss the next RAPP filing
- Alerts as it files. A push when RAPP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RAPP, by share count.
- Ask anything. An AI agent that reads every RAPP filing and answers with sources.
RAPP alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gault Cheryl | Sell | Sep 30, 2026 | 2,075 | $33.76 |
| Gault Cheryl | Sell | Sep 30, 2026 | 7,925 | $33.04 |
| Ceesay Abraham | Sell | Sep 23, 2026 | 43 | $41.05 |
| Ceesay Abraham | Sell | Sep 23, 2026 | 1,952 | $39.05 |
| Ceesay Abraham | Sell | Sep 23, 2026 | 215 | $39.86 |
| Ceesay Abraham | Sell | Sep 8, 2026 | 1,069 | $46.01 |
| Ceesay Abraham | Sell | Sep 8, 2026 | 7,141 | $45.55 |
| Yeleswaram Krishnaswamy | Sell | Aug 25, 2026 | 20,799 | $50.31 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$36.2M | -$83.1M | -$125.1M |
| Net Income | - | -$78.3M | -$111.5M |
| Balance Sheet | |||
| Total Assets | $155.4M | $314.9M | $512.4M |
| Equity | -$25.6M | $305.4M | $484.7M |
| ROE | - | -25.6% | -23.0% |
| Per Share | |||
| EPS | $-23.10 | $-3.78 | $-2.86 |
| Cash Flow | |||
| Operating CF | -$27.2M | -$64.8M | -$87.5M |
| CapEx | $1.6M | $2.4M | $616K |
Source: XBRL data in Rapport Therapeutics, Inc. (RAPP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RAPP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $827.9M |
| Q1 2026 | 27 | $608.8M |
| Q4 2025 | 25 | $596.9M |
| Q3 2025 | 24 | $513.5M |
| Q2 2025 | 17 | $155.7M |
| Q1 2025 | 14 | $111.2M |
| Q4 2024 | 8 | $164.9M |
| Q3 2024 | 6 | $63.8M |
- BlackRock+193.8K (+8%)
- Dimensional Fund Advisors+137.6K (+61%)
- Morgan Stanley+131.7K (+79%)
- State Street Corp+59.2K (+8%)
- Invesco Ltd+43.5K (+25%)
- Millennium Management−164.6K (-52%)
- T. Rowe Price Group−79.0K (-9%)
- Citigroup−54.4K (-69%)
- Bank of America Corp−34.8K (-31%)
- Goldman Sachs Group−31.8K (-1%)
- Citadel Advisors LLC+82.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RAPP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RAPP SEC filings: frequently asked questions
Are RAPP insiders buying or selling?
In the last 90 days, Rapport Therapeutics, Inc. (RAPP) officers, directors and 10% owners reported no open-market purchases and 21 open-market sales worth $7.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RAPP stock?
As of June 30, 2026, the largest Rapport Therapeutics, Inc. (RAPP) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($298.9 million), Goldman Sachs Group ($121.3 million), BlackRock ($112.5 million), Johnson & Johnson ($74.4 million), Vanguard Capital Management LLC ($56.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did RAPP report in its latest 8-K?
Rapport Therapeutics, Inc. (RAPP) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results and business highlights announced for quarter ended June 30, 2026.
What are the latest RAPP SEC filings?
Rapport Therapeutics, Inc. (RAPP) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on October 1, 2026.
What is RAPP's SEC CIK number?
Rapport Therapeutics, Inc. (RAPP)'s SEC Central Index Key (CIK) is 2012593. EDGAR lists every RAPP filing under that number.
Ask anything about RAPP
The research agent reads RAPP's filings, financials, insider trades and 13F holders, then answers with sources.